TC Biopharm (Holdings) Plc (TCBP)

0.3900 +0.0221 (+6.01%) As of 12:39PM EST. Market open.

TC Biopharm (Holdings) Plc

Maxim 1
2 Parklands Way Holytown
Motherwell ML1 4WR
United Kingdom
44 14 1433 7557
https://tcbiopharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 60

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Bryan L. Kobel	CEO & Director	N/A	N/A	1981
Mr. Martin E. Thorp	CFO & Director	N/A	N/A	1952
Mr. Christopher Camarra	Executive Vice President of Communications	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Corporate governance

TC Biopharm (Holdings) Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.